Co-Diagnostics anticipates India TB test commercialization by Q3 ’26 while exploring CoSara SPAC options (NASDAQ:CODX)April 1, 2026
Share Facebook Twitter LinkedIn Pinterest Email S&P Global Australia PMI falls to 49.8, ending five-month growth streak
Co-Diagnostics anticipates India TB test commercialization by Q3 ’26 while exploring CoSara SPAC options (NASDAQ:CODX)April 1, 2026
NCino outlines fiscal 2027 free cash flow of $132M-$137M while targeting 10% ACV growth (NASDAQ:NCNO)April 1, 2026
TOMI projects $12M 2026 revenue as it targets recurring orders and expands a $20M iHP opportunity book (NASDAQ:TOMZ)April 1, 2026
